CervoMed Inc. 10-Q

ITEM 5. OTHER INFORMATION   None.     ITEM 6. EXHIBITS   See attached Exhibit Index.   21     DIFFUSION PHARMACEUTICALS INC.   QUARTERLY REPORT ON FORM 10-Q EXHIBIT INDEX     Exhibit No. Description Method of Filing 3.1 Certificate of Amendment to the Certificate of Incorporation, as amended, of Diffusion Pharmaceuticals Inc. Incorporated by reference to Exhibit 3.1 to the registrant's current report on Form 8-K filed on April 18, 2022 3.2 Amendment to the Bylaws, as amended, of Diffusion Pharmaceuticals Inc., effective March 18, 2022 Incorporated by reference to Exhibit 3.2 to the registrant's current report on Form 8-K filed on March 18, 2022 3.3 Certificate of Designation of Preferences, Rights, and Limitations of Series C Convertible Preferred Stock Incorporated by reference to Exhibit 3.1 to the registrant's current report on Form 8-K filed on March 18, 2022 10.1 Form of Subscription Agreement between Diffusion Pharmaceuticals Inc. and the investors named therein, dated March 18, 2022 Incorporated by reference to Exhibit 10.1 to the registrant's current report on Form 8-K filed on March 18, 2022 31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and SEC Rule 13a-14(a) Filed herewith 31.2 Certification of principal financial officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and SEC Rule 13a-14(a) Filed herewith 32.1 Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Furnished herewith 32.2 Certification of principal financial officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Furnished herewith 101 The following materials from Diffusion’s quarterly report on Form 10-Q for the quarter ended March 31, 2022, formatted in Inline XBRL (Extensible Business Reporting Language): (i) the Unaudited Consolidated Balance Sheets, (ii) the Unaudited Consolidated Statements of Operations, (iii) the Unaudited Consolidated Statement of Changes in Stockholders’ Equity, (iv) the Unaudited Consolidated Statements of Cash Flows, and (v) Notes to Unaudited Consolidated Financial Statements Filed herewith 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).     22     SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.   Date: May 12, 2022       DIFFUSION PHARMACEUTICALS INC.                             By: /s/ Robert J. Cobuzzi, Jr., Ph.D.       Robert J. Cobuzzi, Jr., Ph.D.               President and Chief Executive Officer       (Principal Executive Officer)                     By: /s/ William Hornung       William Hornung       Chief Financial Officer       (Principal Financial and Accounting Officer)     23